SMFR - SMFR STOCK NEWS

Sema4 (NASDAQ: SMFR) announced that its health intelligence platform, Centrellis, has received HITRUST CSF Certification, confirming compliance with strict health information security regulations. This certification highlights Sema4’s dedication to data security and patient privacy. With approximately 12 million de-identified clinical records, including over 500,000 genomic profiles, Centrellis aims to enhance personalized medicine and health outcomes. The achievement places Sema4 among elite organizations, demonstrating its commitment to rigorous information risk management protocols.

Sema4 (Nasdaq: SMFR) and Icahn Mount Sinai published a study in Nature Communications, identifying new targets for early-stage invasive lung adenocarcinoma treatment. The research combines in silico, in vitro, and in vivo methods to find a gene expression signature that can stratify patients and highlight potential therapeutics. The study emphasizes the importance of early diagnosis for lung adenocarcinoma, a prevalent and aggressive cancer in the U.S. Researchers found aurora kinases as key regulators and potential treatment targets. This advancement may enhance patient outcomes significantly.

Sema4 (NYSE: SMFR) announced the nationwide expansion of its REPRESENT study aimed at addressing disparities in cancer care through comprehensive genetic testing for underserved communities. Launching in 2021, the study aims to create a diverse clinical-genomic dataset to resolve racial, ethnic, and socioeconomic disparities in clinical trials and therapeutics. With a goal to enroll up to 5,000 advanced-stage cancer patients, the study will run at multiple sites, focusing on increasing accessibility to precision oncology testing. Key findings may help improve health outcomes in these populations.

Sema4 Holdings Corp. reported a 37% increase in fourth quarter test volumes, excluding COVID-19 tests, resulting in nearly 83,000 tests. Fourth quarter revenue also grew by 24% to $47.3 million, supporting their full year guidance of $215-225 million. The company is set to close its acquisition of GeneDx by Q2 2022, enhancing its Centrellis platform with extensive genomic data. Despite a net loss of ($40.2 million) for Q4, down from last year's ($125.7 million), Sema4's cash reserves are robust at $400.6 million.

Sema4 (Nasdaq: SMFR) announced it will release its fourth quarter and full year 2021 financial results after market close on March 14, 2022. A conference call with CEO Eric Schadt and CFO Isaac Ro will occur at 4:30 p.m. ET on the same day, allowing stakeholders to discuss the results. The company will also participate in two virtual investor conferences in March, including the Truist Securities AI Symposium and the Cowen 42nd Annual Health Care Conference, enhancing their visibility in the financial community.

Sema4 (Nasdaq: SMFR) and BioSymetrics have announced a strategic partnership to enhance drug discovery using multi-omics approaches. The collaboration aims to initiate up to 10 therapeutic programs in areas such as cardiovascular, rare, and neurological diseases. Utilizing Sema4's Centrellis platform and BioSymetrics' Elion system, the partnership focuses on finding de-risked drug candidates. Their initial project targets atherosclerosis, with plans to follow up with three additional rare disease programs.

Sema4 (Nasdaq: SMFR) announced its participation in upcoming virtual investor conferences. The company will hold a fireside chat and one-on-one meetings at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 17, 2022, at 10:00 a.m. ET. Furthermore, Sema4 will present at the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 2:20 p.m. ET, with a subsequent live and archived webcast available on its investor relations website.

Sema4 is focused on transforming healthcare through AI-driven genomic and clinical data insights.

Sema4 has appointed industry veteran Jerry Conway as Senior Vice President of Market Access to enhance coverage and reimbursement capabilities for its genomic solutions. With over 30 years of experience, Conway will lead initiatives aimed at improving partnerships with payers and clinicians. His appointment is part of Sema4's strategy to expand its Market Access team and strengthen its position in the healthcare market. The focus will be on value-based payment models, demonstrating the effectiveness of Sema4's offerings in optimizing health outcomes and reducing costs.